Profile data is unavailable for this security.
About the company
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
- Revenue in SEK (TTM)127.01m
- Net income in SEK30.68m
- Incorporated1999
- Employees36.00
- LocationGenovis ABMedicon Village, Scheelevagen 2LUND 223 63SwedenSWE
- Phone+46 46101230
- Fax+46 46128020
- Websitehttps://www.genovis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infant Bacterial Therapeutics AB | 0.00 | -123.07m | 1.21bn | 8.00 | -- | 4.11 | -- | -- | -9.90 | -9.90 | 0.00 | 22.65 | 0.00 | -- | -- | 0.00 | -35.11 | -16.11 | -38.65 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Arcticzymes Technologies ASA | 117.99m | 16.89m | 1.26bn | 61.00 | 74.66 | 4.00 | 54.13 | 10.65 | 0.3302 | 0.3302 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | -- | 5.10 | 15.52 | 5.44 | 17.16 | 95.50 | 96.69 | 14.31 | 33.10 | 12.14 | -- | 0.0327 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
| XSpray Pharma AB (publ) | 0.00 | -212.58m | 1.59bn | 26.00 | -- | 2.90 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Photocure ASA | 513.54m | 4.12m | 1.61bn | 106.00 | 397.45 | 3.32 | 49.53 | 3.13 | 0.149 | 0.149 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | -- | 0.5786 | -3.09 | 0.6548 | -3.56 | 94.65 | 93.64 | 0.802 | -5.19 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
| Devyser Diagnostics AB | 180.50m | -45.90m | 1.63bn | 124.00 | -- | 4.35 | -- | 9.02 | -2.83 | -2.83 | 11.13 | 23.00 | 0.3671 | 1.56 | 5.11 | 1,529,661.00 | -9.33 | -8.97 | -10.65 | -10.15 | 84.76 | 80.14 | -25.43 | -23.91 | 4.34 | -- | 0.1543 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Nanoform Finland Oyj | 29.78m | -240.92m | 1.91bn | 165.00 | -- | 2.25 | -- | 64.08 | -0.2674 | -0.2674 | 0.0331 | 0.8535 | 0.0287 | 138.93 | 4.11 | 15,548.42 | -23.22 | -27.13 | -25.12 | -29.48 | -507.09 | -604.26 | -809.08 | -1,023.70 | 8.16 | -- | 0.0964 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| BioInvent International AB | 61.15m | -334.52m | 1.99bn | 109.00 | -- | 1.62 | -- | 32.60 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Vicore Pharma Holding AB | 104.24m | -212.94m | 2.12bn | 26.00 | -- | 4.33 | -- | 20.30 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 62.80m | -326.90m | 2.20bn | 30.00 | -- | 4.66 | -- | 35.03 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Probi AB | 607.54m | -602.00k | 2.34bn | 167.00 | -- | 1.64 | 24.34 | 3.84 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Genovis AB | 127.01m | 30.68m | 2.34bn | 36.00 | 76.29 | 11.41 | 56.47 | 18.43 | 0.4686 | 0.4686 | 1.94 | 3.13 | 0.5084 | -- | -- | 3,432,784.00 | 12.28 | 18.56 | 13.37 | 21.45 | 66.09 | 65.51 | 24.15 | 23.88 | -- | -- | 0.2769 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Hansa Biopharma AB | 165.88m | -844.88m | 2.54bn | 166.00 | -- | -- | -- | 15.33 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
Data as of May 22 2024. Currency figures normalised to Genovis AB's reporting currency: Swedish Krona SEK
34.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 28 Apr 2023 | 3.69m | 5.64% |
| �landsbanken Abp (Private Banking)as of 31 Aug 2023 | 3.66m | 5.60% |
| Teknik Innovation Norden Fonder ABas of 31 Aug 2023 | 3.32m | 5.07% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 3.10m | 4.74% |
| Andra AP-fondenas of 31 Aug 2023 | 2.23m | 3.41% |
| Aktia Bank Plc (Investment Management)as of 31 Aug 2023 | 1.88m | 2.87% |
| Danske Bank A/S (Investment Management)as of 30 Apr 2024 | 1.57m | 2.40% |
| Handelsbanken Fonder ABas of 30 Apr 2024 | 1.50m | 2.29% |
| Aktia Fondbolag Abas of 30 Apr 2024 | 1.01m | 1.54% |
| Lonvia Capital SASUas of 30 Jun 2023 | 731.48k | 1.12% |
More ▼
Data from 30 Jun 2021 - 30 Apr 2024Source: FactSet Research Systems Inc.
